Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. On October 6, 2010, he acquired 9 Ordinary shares through the re-investment of dividends under a Personal Equity Plan at a price of £12.76 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of Mr. S M Bicknell and his role within the company to assess the significance of the transaction.
- Confirm the share price of £12.76 against market data for October 6, 2010.
- Note that this filing does not reflect broader company performance or financial health.